Trial Purpose

The primary objectives of this study are to compare MK-2870 to Treatment of Physician’s Choice (TPC) with respect to progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR), and overall survival (OS). The primary hypotheses are that MK-2870 is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and that MK-2870 is superior to TPC with respect to OS.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT06132958

When speaking to your doctor, please have the trial identifier number available.

About The Trial

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in approximately 1,000 to 5,000 volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices.

Trial start Icon

Dates

  • Actual study start date December 6, 2023
  • Estimated primary completion date January 10, 2028
  • Estimated study completion date January 10, 2028

Eligibility

Conditions Icon

Conditions

Endometrial Cancer

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

Female

Trial locations